Articles related to KIDNEY CANCER/RCC

Understanding the impact of lymphovascular invasion on overall survival in RCC patients is crucial for surgical decision-making and postoperative care.

Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.

Discover a holistic perspective on advanced bladder and renal cell cancers management, encompassing everything from pathogenesis to adverse event mitigation. Let’s dive into the “Advanced Bladder and Renal Cell Cancers Management” webcast, released on April 30, 2023, offering valuable 1.00 ANCC contact hour, inclusive of 0.75 pharmacology hours. Presented by expert Mary W. Dunn, MSN, RN, OCN, NP-C from the University of North Carolina, this program targets oncology nurses, nurse navigators, advanced nursing providers, and nurses from other cancer-related subspecialties. It remains available until April 30, 2024, leaving ample time to gain this crucial knowledge. Primarily, this webcast zeroes in on bladder cancer (BC), a malignancy notorious for its high mortality rate, and renal cell carcinoma (RCC), a top-10 common cancer. Unfortunately, BC’s 5% survival rate for metastatic disease cases paints a grim picture. Luckily, hope emerges in the form of novel therapeutic agents for advanced, recurrent, and metastatic BC and RCC. Next, the program navigates through the pathogenesis of these cancers. Equipped with this knowledge, healthcare providers can better understand the intricacies of disease progression. As the treatment landscape rapidly evolves, so does the complexity in selection, sequencing, and adverse event (AE) management. Thus, the webcast outlines how to […]

Cabozantinib plus nivolumab and ipilimumab (C-N-I) is a new combination therapy for patients with advanced renal cell carcinoma (RCC). In a phase 3 clinical trial, C-N-I was shown to be superior to sunitinib in terms of progression-free survival (PFS) and overall survival (OS). The trial enrolled 823 patients with advanced RCC who had not received prior systemic therapy. Patients were randomly assigned to receive either C-N-I (n=412) or sunitinib (n=411). The primary endpoint of the trial was PFS, and the secondary endpoint was OS. At a median follow-up of 24 months, patients who received C-N-I had a significantly longer PFS than patients who received sunitinib. The median OS for patients who received C-N-I was not reached, while the median OS for patients who received sunitinib was 22.8 months.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

Pembrolizumab was randomly given to 496 patients, while a placebo was given to 498. The estimated percentage of patients still alive at 24 months was 96.6% in the pembrolizumab group and 93.5% in the placebo group. Pembrolizumab therapy was associated with a significantly longer disease-free survival than placebo, and there were no fatalities brought on by the treatment.